A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Sponsor: Akeso
Terminated
corporate strategy adjustment
Other terminated trials from Akeso
Other Lung Cancer Non-small Cell Stage IV trials with similar outcome
A PHASE3 clinical study on Lung Cancer Non-small Cell Stage IV, this trial is terminated or withdrawn. The trial is conducted by Akeso and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Nov 2022 — May 2024 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2022 — Nov 2022 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
- Akeso Tiancheng, Inc
For direct contact, visit the study record on ClinicalTrials.gov .